CY1116719T1 - Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου - Google Patents
Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακουInfo
- Publication number
- CY1116719T1 CY1116719T1 CY20151100826T CY151100826T CY1116719T1 CY 1116719 T1 CY1116719 T1 CY 1116719T1 CY 20151100826 T CY20151100826 T CY 20151100826T CY 151100826 T CY151100826 T CY 151100826T CY 1116719 T1 CY1116719 T1 CY 1116719T1
- Authority
- CY
- Cyprus
- Prior art keywords
- medicine
- testing methods
- methods
- antibodies testing
- relates
- Prior art date
Links
- 238000012360 testing method Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/05—Investigating sedimentation of particle suspensions in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με μεθόδους ανίχνευσης αντισωμάτων αντι-φαρμάκου. Η παρούσα εφεύρεση σχετίζεται επίσης με μεθόδους παρακολούθησης ασθενών που υποβάλλονται σε αγωγή θεραπευτικού αντισώματος. Η εφεύρεση σχετίζεται επιπλέον με κιτ κατάλληλα για την εφαρμογή των ανωτέρω μεθόδων.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32920110P | 2010-04-29 | 2010-04-29 | |
EP10305455 | 2010-04-29 | ||
EP11716417.8A EP2564202B1 (en) | 2010-04-29 | 2011-04-28 | Methods for detecting anti-drug antibodies |
PCT/EP2011/056732 WO2011135024A1 (en) | 2010-04-29 | 2011-04-28 | Methods for detecting antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1116719T1 true CY1116719T1 (el) | 2017-03-15 |
Family
ID=42246049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20151100826T CY1116719T1 (el) | 2010-04-29 | 2015-09-22 | Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου |
Country Status (19)
Country | Link |
---|---|
US (2) | US9063151B2 (el) |
EP (1) | EP2564202B1 (el) |
JP (1) | JP2013527444A (el) |
KR (1) | KR20130100908A (el) |
CN (1) | CN102884433A (el) |
AU (1) | AU2011247610A1 (el) |
CA (1) | CA2795549A1 (el) |
CY (1) | CY1116719T1 (el) |
DK (1) | DK2564202T3 (el) |
ES (1) | ES2548533T3 (el) |
HR (1) | HRP20151023T1 (el) |
HU (1) | HUE027662T2 (el) |
IL (1) | IL222533A0 (el) |
PL (1) | PL2564202T3 (el) |
PT (1) | PT2564202E (el) |
RS (1) | RS54249B1 (el) |
SI (1) | SI2564202T1 (el) |
SM (1) | SMT201500233B (el) |
WO (1) | WO2011135024A1 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2795549A1 (en) * | 2010-04-29 | 2011-11-03 | Theradiag Sa | Methods for detecting antibodies |
BR112015012482A2 (pt) * | 2012-11-30 | 2017-07-11 | Nestec Sa | ensaios para detecção de autoanticorpos neutralizantes à terapia com produtos biológicos |
MX2016005686A (es) | 2013-10-31 | 2016-08-11 | Regeneron Pharma | Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes. |
EP3084439B1 (en) * | 2013-12-20 | 2018-09-19 | Phadia AB | Analysis of antibodies |
US9778817B2 (en) | 2013-12-31 | 2017-10-03 | Findo, Inc. | Tagging of images based on social network tags or comments |
WO2015166461A1 (en) * | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
EP2982987A1 (en) | 2014-08-08 | 2016-02-10 | Proteomika, S.L. | Lateral flow immunoassays for the detection of antibodies against biological drugs |
MX2017005156A (es) * | 2014-11-05 | 2017-08-08 | Hoffmann La Roche | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. |
CN105277682A (zh) * | 2015-11-17 | 2016-01-27 | 苏州浩欧博生物医药有限公司 | 一种抗TNF-α单抗药物抗体检测试剂盒 |
CN106093413A (zh) * | 2016-07-18 | 2016-11-09 | 本·沙朗 | 一种抗英夫利西抗体elisa检测试剂盒和检测方法 |
KR20180052277A (ko) * | 2016-11-10 | 2018-05-18 | 가톨릭대학교 산학협력단 | 항-제9응고인자 항체의 검출 방법 및 검출 키트 |
CN108535490A (zh) * | 2017-03-06 | 2018-09-14 | 苏州和锐生物科技有限公司 | 生物制剂血药浓度检测方法及试剂 |
WO2019012531A1 (en) * | 2017-07-10 | 2019-01-17 | Rambam Med-Tech Ltd. | ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODY RATES IN BIOLOGICAL DRUG SUBJECTS AND USES THEREOF IN A CUSTOMIZED MEDICINE |
WO2020263450A1 (en) * | 2019-06-25 | 2020-12-30 | Procisedx Inc. | Detection of anti-tnf alpha drug biologics and anti-drug antibodies |
WO2023204378A1 (ko) * | 2022-04-19 | 2023-10-26 | 의료법인 성광의료재단 | 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2520779A1 (en) | 2003-03-31 | 2004-11-11 | Kyowa Hakko Kogyo Co., Ltd. | Agent for intra-airway administration |
US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
ZA200600798B (en) * | 2003-07-29 | 2007-06-27 | Genentech Inc | Assay for human anti CD20 antibodies and uses therefor |
BRPI0708677A2 (pt) * | 2006-03-09 | 2011-06-21 | Hoffmann La Roche | ensaio de anticorpo antifármaco |
CN101506659B (zh) * | 2006-09-12 | 2012-12-12 | 弗·哈夫曼-拉罗切有限公司 | 抗药物抗体测定法 |
WO2008125903A2 (en) * | 2006-12-12 | 2008-10-23 | Chaim Sheba Medical Center | Method of inhibiting an undesired immune response |
AU2008247352A1 (en) | 2007-05-07 | 2008-11-13 | Wyeth | Elimination of interference in immunoassays caused by anti-carbohydrate antibodies |
US8227195B2 (en) * | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
CA2712021A1 (en) | 2008-01-15 | 2009-07-23 | Stichting Sanquin Bloedvoorziening | Methods and kits for detecting antibodies against therapeutic antibodies |
US20110059445A1 (en) * | 2008-03-28 | 2011-03-10 | Paul Rutgeerts | Mucosal gene signatures |
WO2010042031A1 (en) * | 2008-10-07 | 2010-04-15 | Gyros Patent Ab | Semi-sequential assay for detection of an analyte in a sample |
CA2795549A1 (en) * | 2010-04-29 | 2011-11-03 | Theradiag Sa | Methods for detecting antibodies |
-
2011
- 2011-04-28 CA CA2795549A patent/CA2795549A1/en not_active Abandoned
- 2011-04-28 EP EP11716417.8A patent/EP2564202B1/en active Active
- 2011-04-28 PL PL11716417T patent/PL2564202T3/pl unknown
- 2011-04-28 US US13/642,874 patent/US9063151B2/en active Active
- 2011-04-28 KR KR1020127031373A patent/KR20130100908A/ko not_active Application Discontinuation
- 2011-04-28 ES ES11716417.8T patent/ES2548533T3/es active Active
- 2011-04-28 AU AU2011247610A patent/AU2011247610A1/en not_active Abandoned
- 2011-04-28 HU HUE11716417A patent/HUE027662T2/en unknown
- 2011-04-28 RS RS20150620A patent/RS54249B1/en unknown
- 2011-04-28 WO PCT/EP2011/056732 patent/WO2011135024A1/en active Application Filing
- 2011-04-28 DK DK11716417.8T patent/DK2564202T3/en active
- 2011-04-28 CN CN2011800215050A patent/CN102884433A/zh active Pending
- 2011-04-28 JP JP2013506659A patent/JP2013527444A/ja active Pending
- 2011-04-28 PT PT117164178T patent/PT2564202E/pt unknown
- 2011-04-28 SI SI201130609T patent/SI2564202T1/sl unknown
-
2012
- 2012-10-18 IL IL222533A patent/IL222533A0/en unknown
-
2015
- 2015-06-22 US US14/745,765 patent/US9651560B2/en active Active
- 2015-09-22 CY CY20151100826T patent/CY1116719T1/el unknown
- 2015-09-28 HR HRP20151023TT patent/HRP20151023T1/hr unknown
- 2015-09-29 SM SM201500233T patent/SMT201500233B/it unknown
Also Published As
Publication number | Publication date |
---|---|
CA2795549A1 (en) | 2011-11-03 |
SMT201500233B (it) | 2016-01-08 |
IL222533A0 (en) | 2012-12-31 |
EP2564202B1 (en) | 2015-07-01 |
CN102884433A (zh) | 2013-01-16 |
WO2011135024A1 (en) | 2011-11-03 |
HRP20151023T1 (hr) | 2015-11-06 |
ES2548533T3 (es) | 2015-10-19 |
JP2013527444A (ja) | 2013-06-27 |
DK2564202T3 (en) | 2015-10-05 |
AU2011247610A1 (en) | 2012-12-13 |
PL2564202T3 (pl) | 2016-04-29 |
US20130108631A1 (en) | 2013-05-02 |
RS54249B1 (en) | 2016-02-29 |
SI2564202T1 (sl) | 2015-12-31 |
US9063151B2 (en) | 2015-06-23 |
PT2564202E (pt) | 2015-10-20 |
US9651560B2 (en) | 2017-05-16 |
US20150285815A1 (en) | 2015-10-08 |
EP2564202A1 (en) | 2013-03-06 |
KR20130100908A (ko) | 2013-09-12 |
HUE027662T2 (en) | 2016-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1116719T1 (el) | Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου | |
CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
CY1120913T1 (el) | Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
CY1124428T1 (el) | Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1 | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1122073T1 (el) | Μορια αντισωματος που εχουν εξειδικευση για τον ανθρωπινο οχ40 | |
CY1119255T1 (el) | Μεθοδος, σωληναριο και συσκευη για την παρασκευη συνθεσης επουλωσης πληγης | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
TR201904638T4 (tr) | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. | |
MX2014016014A (es) | Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon. | |
EA201491541A1 (ru) | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ | |
UY34343A (es) | Proteinas de unión al antígeno cd27l | |
EA201391540A1 (ru) | Агонисты fgfr1 и способы их применения | |
CY1123172T1 (el) | Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα | |
MA38632B1 (fr) | Anticorps anti-récepteur de transferrine et procédés d'utilisation | |
EA201591417A1 (ru) | Новый способ диагностики депрессии и мониторинга эффективности терапии | |
CY1118530T1 (el) | Glyx-13 για χρηση σε μεθοδο θεραπευτικης αγωγης ανθεκτικης σε θεραπεια καταθλιψης | |
PH12014502399B1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
UY34394A (es) | Polipéptidos de anticuerpos que antagonizan cd40l | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
GB201202223D0 (en) | Immunoassay for pyrrolidinophenones | |
GB201305223D0 (en) | Reflection detection type measurement apparatus for skin autofluorescence |